您的位置:首页>>分析化学>>药物分析标准品>>M4652 MLN8237 1028486-01-2
Cat. Number
M4652
Chemical Name
M4652 MLN8237 1028486-01-2
CAS Number
1028486-01-2
Mol. Formula
C27H20ClFN4O4
Mol. Weight
518.92
Qty 1
1mg
Qty 2
10mg
Appearance
Pale Yellow Powder
Application Notes
≥98%
Synonym
Alisertib
Solubility
DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Storage condition
-20°C
References

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.


References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.


下一个:TOZASERTIB上一个:GSK-1070916
在线咨询 联系方式 二维码

服务热线

021-60498804

扫一扫,关注我们